Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nature Medicine

• Publication date

  2016-12-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm.4247PMID 27941792PMCID PMC6548550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An interactive environment for agile analysis and visualization of ChIP-sequencing data

  2016cited by this paper
• GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo.

  2016cited by this paper
• The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

  2015cited by this paper
• An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging

  2015cited by this paper
• Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

  2015cited by this paper
• FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.

  2015cited by this paper
• Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

  2015cited by this paper
• An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

  2014cited by this paper
• Identification of small molecules that support human leukemia stem cell activity ex vivo

  2014cited by this paper
• Integrative analysis of histone ChIP-seq and transcription data using Bayesian mixture models

  2014cited by this paper
• Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

  2014cited by this paper
• Increased proteome coverage by combining PAGE and peptide isoelectric focusing: Comparative study of gel-based separation approaches

  2013cited by this paper
• DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding.

  2013influential reference
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer

  2013cited by this paper
• Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

  2013cited by this paper
• Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

  2013cited by this paper
• The role of mutations in epigenetic regulators in myeloid malignancies

  2012cited by this paper
• Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

  2012cited by this paper
• Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.

  2012cited by this paper
• ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

  2012cited by this paper
• REST–Mediated Recruitment of Polycomb Repressor Complexes in Mammalian Cells

  2012cited by this paper
• Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.

  2012cited by this paper
• Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

  2012cited by this paper
• TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

  2011cited by this paper
• CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells

  2011cited by this paper
• EZH2 mutational status predicts poor survival in myelofibrosis.

  2011cited by this paper
• The treatment of elderly patients with acute myeloid leukemia.

  2011cited by this paper
• ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

  2011cited by this paper
• Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability*

  2011cited by this paper
• Novel approaches to the treatment of acute myeloid leukemia.

  2011cited by this paper
• The Polycomb complex PRC2 and its mark in life

  2011cited by this paper
• Andromeda: a peptide search engine integrated into the MaxQuant environment.

  2011cited by this paper
• Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells

  2010cited by this paper
• Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

  2010cited by this paper
• A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

  2010cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

  2010cited by this paper
• Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.

  2010cited by this paper
• Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

  2009cited by this paper
• Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads

  2009cited by this paper
• HOXA9 is required for survival in human MLL-rearranged acute leukemias.

  2009cited by this paper
• Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

  2009cited by this paper
• Genome-scale DNA methylation maps of pluripotent and differentiated cells

  2008influential reference
• MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

  2008cited by this paper
• In-gel digestion for mass spectrometric characterization of proteins and proteomes

  2006cited by this paper
• Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

  2006cited by this paper
• MLL-rearranged leukemias: insights from gene expression profiling.

  2003cited by this paper
• The polycomb group protein EZH2 is involved in progression of prostate cancer

  2002cited by this paper
• The Polycomb-Group Gene Ezh2 Is Required for Early Mouse Development

  2001cited by this paper
• Ubiquitin and proteasomes: Themes and variations on ubiquitylation

  2001cited by this paper
• The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development

  2001cited by this paper
• Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development.

  1999cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999cited by this paper
• Hop as an Adaptor in the Heat Shock Protein 70 (Hsp70) and Hsp90 Chaperone Machinery*

  1998cited by this paper
• [Treatment of elderly patients with acute myeloid leukemia].

  1997cited by this paper
• Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells.

  1994cited by this paper
• [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

  1987cited by this paper
• Low SMC 1 A protein expression predicts poor survival in acute myeloid leukemia

  year unknowncited by this paper

• Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells

  2026cites this paper
• Histone modifications in biological age determination: mechanisms, biomarkers, and therapeutic perspectives.

  2026cites this paper
• Epigenetic regulation of cancer stemness

  2025cites this paper
• Polycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistance

  2025cites this paper
• Correlation of EZH2 and related signaling molecules p-STAT3, p-ERK1/2, and MYC overexpression with H3K27 trimethylation associates differently to disease progression in JAK2 mutation -positive and -negative myeloid neoplasms.

  2025cites this paper
• EZH2 Gene Expression and SOCS1 Gene Methylation in Acute Myeloid Leukemia: Unraveling Epigenetic Interactions and Clinical Implications

  2025cites this paper
• GMP-like and MLP-like Subpopulations of Hematopoietic Stem and Progenitor Cells Harboring Mutated EZH2 and TP53 at Diagnosis Promote Acute Myeloid Leukemia Relapse: Data of Combined Molecular, Functional, and Genomic Single-Stem-Cell Analyses

  2025cites this paper
• Epigenetic dysregulation in acute myeloid leukemia

  2025cites this paper
• Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance

  2025cites this paper
• Genome-wide CRISPR/Cas9 screening identifies PTGR2 as a potential therapeutic target for sunitinib resistance in clear cell renal cell carcinoma

  2025cites this paper
• RNA-Binding Protein NF90 Mediates Polycomb-Independent Transactivation by EZH2 to Promote Cancer Growth

  2025cites this paper
• From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights

  2025cites this paper
• Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies

  2025cites this paper
• Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis

  2025cites this paper
• Cathepsin D promotes acute myeloid leukemia progression through stabilization of the anti-apoptotic proteins

  2025cites this paper
• Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells

  2025cites this paper
• Mechanism of Astragaloside-Brucea javanica oil nanoemulsion against oral squamous cell carcinoma through CDK1/MTFR2: Network pharmacology, bioinformatics, and experimental studies

  2025cites this paper
• Meet PRC2: A new player in T-cell acute lymphoblastic leukemia.

  2025cites this paper
• H3K27me3 and HOXA9 expression predict prognosis in pediatric acute myeloid leukemia: an epigenetic-transcriptional correlation study

  2025cites this paper
• Identification of novel biomarkers and potential molecular targets for uterine cancer using network-based approach.

  2024cites this paper
• EZH2-mediated development of therapeutic resistance in cancer.

  2024cites this paper
• Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges

  2024cites this paper
• Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia

  2024cites this paper
• HSP90AA1 is an unfavorable prognostic factor for hepatocellular carcinoma and contributes to tumorigenesis and chemotherapy resistance

  2024cites this paper
• HOXA9 versus HOXB9; particular focus on their controversial role in tumor pathogenesis

  2024cites this paper
• Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.

  2024cites this paper
• HNCDrugResDb: a platform for deciphering drug resistance in head and neck cancers

  2024cites this paper
• Telomere dysfunction alters intestinal stem cell dynamics to promote cancer.

  2024cites this paper
• Targeting chromatin modifying complexes in acute myeloid leukemia

  2024cites this paper
• The epigenetic role of EZH2 in acute myeloid leukemia

  2024cites this paper
• Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options.

  2024cites this paper
• FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia

  2024cites this paper
• Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic

  2024cites this paper
• SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters

  2023cites this paper
• Verification of fasting-mimicking diet to assist monotherapy of human cancer-bearing models.

  2023cites this paper
• Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment

  2023cites this paper
• P327: LOSS OF POLYCOMB REPRESSIVE COMPLEX 2 FUNCTION CAUSES ASPARAGINASE RESISTANCE IN T-ACUTE LYMPHOBLASTIC LEUKAEMIA THROUGH DECREASED WNT PATHWAY ACTIVITY

  2023cites this paper
• Comprehensive analysis of HOXC8 associated with tumor microenvironment characteristics in colorectal cancer

  2023cites this paper
• Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

  2023cites this paper
• The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia

  2023cites this paper
• TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy

  2023cites this paper
• The roles of EZH2 in cancer and its inhibitors

  2023cites this paper
• Tumor-suppressive functions of protein lysine methyltransferases

  2023cites this paper
• DNA methylation of HOX genes and its clinical implications in cancer.

  2023cites this paper
• Polycomb Repressive Complex 2 in Oncology.

  2023cites this paper
• Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches

  2023cites this paper
• Polycomb Alterations in Acute Myeloid Leukaemia: From Structure to Function

  2023cites this paper
• EZH2 can be used as a therapeutic agent for inhibiting endothelial dysfunction.

  2023cites this paper
• MIR143HG promotes methylation of transcription factor HOXB7 promoter by recruiting methyltransferase DNMT1 to prevent the progression of colon cancer

  2023cites this paper
• Acute myeloid leukemia: novel mutations and their clinical implications.

  2023influential citation
• A guide to epigenetics in leukaemia stem cells

  2023cites this paper
• Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations

  2023cites this paper
• Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis

  2023cites this paper
• Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells

  2023cites this paper
• The epigenome and the many facets of cancer drug tolerance.

  2023cites this paper
• Development of MDS in Pediatric Patients with GATA2 Deficiency: Increased Histone Trimethylation and Deregulated Apoptosis as Potential Drivers of Transformation

  2023cites this paper
• Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC.

  2023cites this paper
• Crosstalk between Noncoding RNAs and the Epigenetics Machinery in Pediatric Tumors and Their Microenvironment

  2023cites this paper
• Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML.

  2023cites this paper
• Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

  2023cites this paper
• How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia

  2022cites this paper
• Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium

  2022cites this paper
• Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes

  2022cites this paper
• CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer

  2022cites this paper
• Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis

  2022influential citation
• Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells

  2022cites this paper
• H3K27me3 conditions chemotolerance in triple-negative breast cancer

  2022cites this paper
• Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.

  2022cites this paper
• Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis

  2022cites this paper
• Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium

  2022cites this paper
• CRISPR-Cas9-mediated gene therapy in lung cancer

  2022cites this paper
• High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia

  2022cites this paper
• Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.

  2022cites this paper
• Low expression of the metabolism-related gene SLC25A21 predicts unfavourable prognosis in patients with acute myeloid leukaemia

  2022cites this paper
• SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation

  2022cites this paper
• High HOXA9 gene expression predicts response to chemotherapy and prognosis of high-grade serous ovarian cancer patients

  2022cites this paper
• Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters

  2022cites this paper
• The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy

  2022influential citation
• Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

  2022cites this paper
• Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells

  2022cites this paper
• Tumor-derived miRNAs as tumor microenvironment regulators for synergistic therapeutic options

  2022cites this paper
• Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives

  2022cites this paper
• DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A

  2021cites this paper
• Epigenetic dysregulation in myeloid malignancies.

  2021cites this paper
• Chromosomal Instability in Acute Myeloid Leukemia

  2021cites this paper
• Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia

  2021cites this paper
• The significance of CUX1 and chromosome 7 in myeloid malignancies

  2021cites this paper
• Anticancer chiral and racemic ternary copper(II) complexes: multiple mechanisms and epigenetic histone methyltransferase enzymes as novel targets

  2021cites this paper
• Vitamin C promotes anti-leukemia of DZNep in acute myeloid leukemia.

  2021cites this paper
• Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review

  2021cites this paper
• Study of HOTAIR LncRNA in AML patients in context to FLT3-ITD and NPM1 mutations status

  2021cites this paper
• Supplemental Data EZH 2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity

  2021cites this paper
• miR-26a Reverses Multidrug Resistance in Osteosarcoma by Targeting MCL1

  2021cites this paper
• Molecular regulators of HOXA9 in acute myeloid leukemia

  2021cites this paper
• Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy

  2021cites this paper
• BAMscale: quanti�cation of next-generation sequencing peaks and generation of scaled coverage tracks

  2021cites this paper
• Epigenetic targeting for lung cancer treatment via CRISPR/Cas9 technology

  2021cites this paper
• CD33‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells

  2021cites this paper
• EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

  2021cites this paper
• Therapeutic Opportunities of Targeting Canonical and Noncanonical PcG/TrxG Functions in Acute Myeloid Leukemia.

  2021cites this paper